Understanding how the immune system detects HIV-1 infection
In vivo innate immune sensing of HIV-1 infection
This study is looking at how the body's first line of defense reacts to HIV-1 right after infection, using special mice to help understand which immune cells are involved, and the findings could help improve vaccines and treatments for people living with HIV.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11009442 on NIH RePORTER |
What this research studies
This research investigates the early immune responses to HIV-1 infection, focusing on how the innate immune system recognizes the virus and the subsequent effects on disease progression. By using a specialized mouse model, researchers aim to identify the specific immune cells and pathways involved in responding to HIV-1. The study will analyze the immune events that occur immediately after infection, which are crucial for developing effective vaccines and treatments. Patients may benefit from insights gained about how to enhance immune responses against HIV-1.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of contracting HIV-1, including those with multiple sexual partners or those who engage in intravenous drug use.
Not a fit: Patients who are already living with advanced AIDS or those who are not at risk of HIV-1 infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines and therapies for HIV-1, ultimately reducing the incidence of AIDS.
How similar studies have performed: Previous research has shown promise in understanding immune responses to viral infections, but this specific approach using the MISTRG mouse model is relatively novel.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Rongvaux, Anthony — Fred Hutchinson Cancer Center
- Study coordinator: Rongvaux, Anthony
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.